Patents by Inventor Barbara Haeberlin

Barbara Haeberlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10314784
    Abstract: A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: June 11, 2019
    Assignee: Novartis AG
    Inventors: Barbara Haeberlin, Frank Stowasser, Wolfgang Wirth, Anton Baumberger, Stephan Abel, Sebastian Kaerger, Thomas Kieckbusch
  • Publication number: 20160081934
    Abstract: A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.
    Type: Application
    Filed: December 7, 2015
    Publication date: March 24, 2016
    Applicant: Novartis AG
    Inventors: Barbara Haeberlin, Frank Stowasser, Wolfgang Wirth, Anton Baumberger, Stephen Abel, Sebastian Kaerger, Thomas Kieckbusch
  • Publication number: 20150224194
    Abstract: A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.
    Type: Application
    Filed: April 21, 2015
    Publication date: August 13, 2015
    Applicant: Novartis AG
    Inventors: Barbara Haeberlin, Frank Stowasser, Wolfgang Wirth, Anton Baumberger, Stephan Abel, Sebastian Kaerger, Thomas Kieckbusch
  • Patent number: 8722664
    Abstract: Spontaneously dispersible N-benzoyl-staurosporine compositions are disclosed for oral administration having high bioavailability levels and reduced variability of bioavailability levels of N-benzoyl-staurosporine, as well as their preparation and use in medical treatment.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: May 13, 2014
    Assignee: Novartis AG
    Inventors: Graham Paul Matthews, Barbara Haeberlin
  • Publication number: 20140056974
    Abstract: Spontaneously dispersible N-benzoyl-staurosporine compositions are discussed for oral administration having high bioavailability levels and reduced variability of bioavailability levels of N-benzoyl-staurosporine, as well as their preparation and use in medical treatment.
    Type: Application
    Filed: October 15, 2013
    Publication date: February 27, 2014
    Applicant: NOVARTIS AG
    Inventors: Graham Paul Matthews, Barbara Haeberlin
  • Patent number: 8617598
    Abstract: A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: December 31, 2013
    Assignee: Novartis AG
    Inventors: Barbara Haeberlin, Andrea Kramer, Silvia Heuerding
  • Patent number: 8575147
    Abstract: Spontaneously dispersible N-benzoyl-staurosporine compositions are discussed for oral administration having high bioavailability levels and reduced variability of bioavailability levels of N-benzoyl-staurosporine, as well as their preparation and use in medical treatment.
    Type: Grant
    Filed: September 21, 2007
    Date of Patent: November 5, 2013
    Assignee: Novartis AG
    Inventors: Graham Paul Matthews, Barbara Haeberlin
  • Publication number: 20120289536
    Abstract: A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.
    Type: Application
    Filed: June 5, 2012
    Publication date: November 15, 2012
    Inventors: Barbara Haeberlin, Andrea Kramer, Silvia Heuerding
  • Publication number: 20120065174
    Abstract: A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.
    Type: Application
    Filed: October 12, 2011
    Publication date: March 15, 2012
    Inventors: Barbara Haeberlin, Frank Stowasser, Wolfgang Wirth, Anton Baumberger, Stephan Abel, Sebastian Kaerger, Thomas Kieckbusch
  • Publication number: 20110306630
    Abstract: A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.
    Type: Application
    Filed: June 13, 2011
    Publication date: December 15, 2011
    Inventors: Barbara Haeberlin, Andrea Kramer, Silvia Heuerding
  • Publication number: 20110182830
    Abstract: Various embodiments of the present invention provide drug products, inhalation systems and methods of treating respiratory diseases. Several embodiments provide an inhalation system including a pressurized metered dose inhaler and a chamber. The chamber may be an anti-static chamber with a chamber volume of about 145 milliliters (ml) to about 200 ml.
    Type: Application
    Filed: January 9, 2009
    Publication date: July 28, 2011
    Inventors: Ying Li, Jill K. Sherwood, Barbara Haeberlin, Ian Laurence Scott
  • Publication number: 20110152201
    Abstract: This invention provides an emulsion, e.g., microemulsion, pre-concentrate comprising a difficultly soluble active agent and a carrier medium. The active agent may, e.g., be a cyclosporin or a macrolide.
    Type: Application
    Filed: February 28, 2011
    Publication date: June 23, 2011
    Inventors: Michael Ambühl, Barbara Lückel, Friedrich Richter, Barbara Häberlin, Armin Meinzer
  • Publication number: 20100221331
    Abstract: The present invention provides a pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide. The composition comprises 1 to 5% colloidal silicon dioxide by weight.
    Type: Application
    Filed: May 10, 2010
    Publication date: September 2, 2010
    Applicant: NOVARTIS AG
    Inventors: Barbara Haeberlin, Andrea Kramer, Silvia Heuerding
  • Publication number: 20100215734
    Abstract: The present invention provides a pharmaceutical composition in solid form comprising a poorly water soluble drug, a solubilizing component, and a surfactant which is semisolid or solid. The poorly soluble drug may e.g. be a cyclosporin or a macrolide.
    Type: Application
    Filed: May 5, 2010
    Publication date: August 26, 2010
    Inventors: Michael Ambühl, Barbara Haeberlin, Barbara Lückel, Armin Meinzer, Olivier Lambert, Laurent Marchal
  • Publication number: 20100166671
    Abstract: Medicaments comprising (A) an antimuscarinic agent, (B) a beta-2 adrenoreceptor agonist and (C) a corticosteroid for the treatment of inflammatory or obstructive airways diseases.
    Type: Application
    Filed: August 29, 2007
    Publication date: July 1, 2010
    Inventors: Stephen P. Collingwood, Barbara Haeberlin
  • Publication number: 20090209502
    Abstract: A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.
    Type: Application
    Filed: June 28, 2007
    Publication date: August 20, 2009
    Inventors: Barbara Haeberlin, Frank Stowasser, Wolfgang Wirth, Anton Baumberger, Stephan Abel, Sebastian Kaerger, Thomas Kieckbusch
  • Publication number: 20080317862
    Abstract: Medicaments comprising (A) an antimuscarinic agent and (B) a corticosteroid for the treatment of inflammatory or obstructive airways diseases.
    Type: Application
    Filed: November 20, 2006
    Publication date: December 25, 2008
    Inventors: Stephen Paul Collingwood, Barbara Haeberlin
  • Publication number: 20080286363
    Abstract: A medicament comprising, separately or together (A) a compound of formula I in free or salt or solvate form, (B) a glycopyrronium salt; and (C) a compound of formula II for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
    Type: Application
    Filed: November 20, 2006
    Publication date: November 20, 2008
    Inventors: Stephen Paul Collingwood, Barbara Haeberlin
  • Publication number: 20080279948
    Abstract: A medicament comprising, separately or together (A) a compound of formula I in free or salt or solvate form, wherein W, Rx, Ry, R1, R2, R3, R4, R5, R6 and R7 have the meanings as indicated in the specification; (B) a glycopyrronium salt; and (C) mometasone furoate; for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
    Type: Application
    Filed: November 20, 2006
    Publication date: November 13, 2008
    Applicant: NXP B.V.
    Inventors: Stephen Paul Collingwood, Barbara Haeberlin
  • Publication number: 20080274189
    Abstract: Medicaments comprising (A) an antimuscarinic agent and (B) a corticosteroid for the treatment of inflammatory or obstructive airways diseases.
    Type: Application
    Filed: November 20, 2006
    Publication date: November 6, 2008
    Inventors: Stephen Paul Collingwood, Barbara Haeberlin